T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial

Haematologica. 2022 Apr 1;107(4):1000-1003. doi: 10.3324/haematol.2021.280300.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Humans
  • Immunity
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Prospective Studies
  • RNA, Messenger / genetics
  • SARS-CoV-2
  • T-Lymphocytes
  • Vaccination


  • Antibodies, Viral
  • RNA, Messenger
  • BNT162 Vaccine

Grants and funding

Funding: this study was supported by grants from the SciLifeLab National COVID-19 Research Program, financed by the Knut and Alice Wallenberg Foundation, the Swedish Research Council, Region Stockholm, the Swedish Blood Cancer Foundation and Karolinska Institutet.